REFERENCES
- Engelhard H H, Duncan H A, Dal, Canto M. Molecular characterization of glioblastoma cell differentiation. Neurosurgery. 1997; 41: 886–896, discussion 96–97. [PUBMED], [INFOTRIEVE], [CSA]
- Driever P H, Knupfer M M, Cinatl J, Wolff J E. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr. 1999; 211: 323–328. [PUBMED], [INFOTRIEVE], [CSA]
- Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105: 1045–1047. [PUBMED], [INFOTRIEVE], [CSA]
- Blaheta R A, Nau H, Michaelis M, Cinatl J, Jr.. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem. 2002; 9: 1417–1433. [PUBMED], [INFOTRIEVE]
- Blaheta R A, Cinatl J, Jr.. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002; 22: 492–511. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kieslich M, Schwabe D, Cinatl J, Jr., Driever P H. Increase of fetal hemoglobin synthesis indicating differentiation induction in children receiving valproic acid. Pediatr Hematol Oncol. 2003; 20: 15–22. [PUBMED], [INFOTRIEVE], [CSA]
- Kaatsch P, Rickert C H, Kuhl J, Schuz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer. 2001; 92: 3155–3164. [PUBMED], [INFOTRIEVE], [CROSSREF]
- McNeil D E, Cote T R, Clegg L, Rorke L B. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol. 2002; 39: 190–194. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yang H J, Nam D H, Wang K C, Kim Y M, Chi J G, Cho B K. Supratentorial primitive neuroectodermal tumor in children: clinical features, treatment outcome and prognostic factors. Childs Nerv Syst. 1999; 15: 377–383. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Timmermann B, Kortmann R D, Kuhl J, et al, Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. 3 J Clin Oncol. 2002; 20: 842–849
- Kraus J A, Felsberg J, Tonn J C, Reifenberger G, Pietsch T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol. 2002; 28: 325–333. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Deininger M H, Grote E, Wickboldt J, Meyermann R. Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. J Neurooncol. 2000; 48: 121–129. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chang S M, Kuhn J G, Robins H I, et al, Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol. 1999; 17: 984–990. [PUBMED], [INFOTRIEVE]
- Buckner J C, Malkin M G, Reed E, et al, Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc. 1999; 74: 137–145. [PUBMED], [INFOTRIEVE], [CSA]
- Defer G L, Adle-Biassette H, Ricolfi F, et al, All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol. 1997; 34: 169–177. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Phuphanich S, Scott C, Fischbach A J, Langer C, Yung W K. All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol. 1997; 34: 193–200. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Baker M J, Brem S, Daniels S, Sherman B, Phuphanich S. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol. 2002; 59: 239–242. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Trouillas P, Honnorat J, Bret P, Jouvet A, Gerard J P. Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J Neurooncol. 2001; 51: 57–66. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cinatl J, Jr., Cinatl J, Scholz M, et al, Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs. 1996; 7: 766–773. [PUBMED], [INFOTRIEVE], [CSA]
- Cinatl J, Jr., Cinatl J, Driever P H, et al, Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs. 1997; 8: 958–963. [PUBMED], [INFOTRIEVE], [CSA]
- Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res. 2002; 26: 495–502. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathol (Berl). 2001; 101: 217–224
- Gottlicher M, Minucci S, Zhu P, et al, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 2001; 20: 6969–6978. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Phiel C J, Zhang F, Huang E Y, Guenther M G, Lazar M A, Klein P S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276: 36734–36741. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chen Y, Sharma R P, Costa R H, Costa E, Grayson D R. On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res. 2002; 30: 2930–2939. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Williams R S, Cheng L, Mudge A W, Harwood A J. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002; 417: 292–295. [PUBMED], [INFOTRIEVE], [CROSSREF]